August 2012
-
Results from a 24-week study comparing GSK’s Anoro Ellipta umeclidinium /vilanterol DPI to Boehringer Ingelheim’s Spiriva Handihaler tiotropium DPI published in Respiratory Medicine show statistically greater improvement in trough FEV1 and weighted mean FEV1 0… Read more . . .
-
Retrophin has announced that Turing Pharmaceuticals will pay $3 million up front for three of Retrophin’s products, including Syntocinon oxytocin nasal spray and ketamine. According to the company, the agreement includes the resignation of Retrophin… Read more . . .
-
Novel Laboratories, Inc. is a fast growing specialty pharmaceutical products development and manufacturing company located in New Jersey. We are looking for experienced, senior level scientists/formulators/engineers for the development of Metered Dose Inhalers, Nasal Sprays… Read more . . .
-
Swedish CRO Inhalation Sciences AB (ISAB) has announced the hires of Mikael Mikko as a product specialist and Iwona Rådberg as an ex vivo and in vivo studies specialist. Mikko, who has a doctorate in… Read more . . .
-
Aptuit has named Manuela Leone as Executive VP, Operations and General Manager of the Aptuit Center for Drug Discovery & Development in Verona, Italy, where the company provides inhaled drug development and clinical supply manufacturing… Read more . . .
-
California-based biopharmaceutical company OrPro Therapeutics says that pre-clinical studies of its lead compound, ORP-100, an inhaled thioredoxin, has shown that ORP-100 reduces the viscosity and adhesiveness of the sputum of cystic fibrosis patients both in… Read more . . .
-
The Portuguese Health Authority (Infarmed) has approved Sandoz’s AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD, triggering a €1.5 million milestone payment to developer Vectura. Sandoz licensed AirFluSal Forspiro from Vectura in… Read more . . .
-
Boehringer Ingelheim has announced that the Striverdi Respimat olodaterol soft mist inhaler is now available in the United States. The FDA approved Striverdi Respimat for the treatment of COPD in July 2014. The company said… Read more . . .
-
California-based CDMO Formex has announced the hires of two new scientists, Ke Shi and Wade Pathak, as well as the acquisition of new spray drying and capsule filling equipment. Formex Senior Director of Business Development… Read more . . .
-
Teva Pharmaceutical has completed a strategic review of its core therapeutic areas and will focus its development efforts on central nervous system and respiratory drugs, the company has announced. According to the announcement, 14 drug… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland